Replies to post #3016 on Acadia Pharmaceuticals Inc. (ACAD)

[north40000]

NEJM provides a partial answer to your questions in an article published in the print version dated 7/22/2021 at pages 309-319, titled “Trial of Pimavanserin in Dementia-Related Psychosis.” We know the Acadia Harmony clinical trial was stopped early for efficacy.

We are not selling our shares of Acadia. I will try to supply a link to that article later tonight, time permitting.

A NEJM editorial appears at pages 372-373, noting that there were 46 million people with various forms of “dementia”, including AD, worldwide. How will FDA regard this data in regard to any label for use negotiations to be conducted in the future is also a question to be answered.